List of Excipients in Branded Drug OMNITROPE

Omnitrope Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Omnitrope is a recombinant human growth hormone product containing somatropin. Its commercial opportunity is driven less by new-molecule exclusivity than by formulation stability, delivery-device compatibility, pediatric usability, preservative strategy, and manufacturing cost. The core excipient system uses phosphate buffering, glycine stabilization, phenol preservation, poloxamer 188 for interfacial protection, and water for injection. This creates opportunities for differentiated presentations, including preservative-free products, low-volume cartridges, improved pen systems, and formulations that reduce cold-chain and handling burdens.

What is Omnitrope and how is it formulated?

Omnitrope is a recombinant somatropin product marketed by Sandoz, a Novartis company. It is supplied as a sterile injectable solution in cartridge and vial presentations, depending on market. U.S. presentations include 5 mg/1.5 mL and 10 mg/1.5 mL cartridges used with an injection device.

The formulation contains:

Component	Functional role
Somatropin	Active recombinant human growth hormone
Sodium phosphate salts	pH control and buffering
Glycine	Protein stabilizer and tonicity contributor
Phenol	Antimicrobial preservative
Poloxamer 188	Surfactant that reduces adsorption and aggregation
Water for injection	Vehicle

The product is stored under refrigerated conditions. The label instructs users to protect the product from freezing and light and to follow specified in-use storage limits after the cartridge or vial is entered.[1]

Why does the excipient system matter?

Somatropin is a protein with sensitivity to aggregation, surface adsorption, agitation, temperature changes, and repeated exposure to air-liquid interfaces. The excipient system must therefore protect:

1. Molecular integrity during refrigerated storage.
2. Potency through repeated dosing.
3. Compatibility with cartridge and pen components.
4. Sterility after initial use.
5. Patient acceptance in a predominantly pediatric population.

The commercial limitation is that each excipient creates a trade-off. Phenol supports multidose sterility but can cause injection-site discomfort or local tolerability concerns. Poloxamer 188 improves interfacial stability but must be controlled because surfactant degradation and subvisible particles can affect product quality. Phosphate buffers provide pH control but can contribute to precipitation or ionic-strength effects during storage and freezing excursions.

What excipient strategy does Omnitrope use?

Omnitrope uses a conventional multidose protein-injection strategy rather than a highly differentiated formulation platform. The combination of glycine, phosphate buffer, phenol, and poloxamer 188 is designed to maintain somatropin stability while permitting repeated administration from a cartridge or vial.

Protein stabilization

Glycine is widely used in biologic formulations as a stabilizing amino acid. It can help control protein-protein interactions and contribute to isotonicity. For somatropin, the key commercial objective is maintaining monomer content and potency throughout the labeled shelf life.

A competing product could pursue an alternative stabilizer system based on:

• Histidine or citrate buffering.
• Sucrose, trehalose, or other nonreducing sugars.
• Amino-acid combinations.
• Reduced or absent surfactant.
• Lower-concentration protein formulations.

Any substitution would require comparative studies covering aggregation, oxidation, deamidation, potency, particulate formation, container closure integrity, and device performance.

Preservative strategy

Phenol permits multidose use, which is important for chronic growth-hormone treatment. A multidose presentation reduces packaging waste and can lower per-dose administration costs.

The principal opportunity is a preservative-free formulation. This could be valuable for patients with local intolerance, repeated injection-site reactions, or sensitivity to phenolic preservatives. A preservative-free product would require a different sterility and packaging strategy, such as:

• Single-dose cartridges.
• Unit-dose prefilled syringes.
• A sterile disposable pen.
• A closed cartridge system with validated in-use protection.
• A formulation with improved aseptic-use robustness.

The commercial trade-off is higher packaging cost and greater device complexity. A preservative-free product is most attractive where reimbursement supports a premium or where adherence and tolerability produce measurable economic benefits.

Surfactant strategy

Poloxamer 188 reduces adsorption of somatropin to glass, plastic, elastomeric components, and air-liquid interfaces. It is particularly relevant to cartridge systems exposed to repeated dose withdrawal and movement during use.

A differentiated product could focus on:

• Lower poloxamer concentration.
• Alternative surfactants.
• More robust container coatings.
• Device materials that reduce protein adsorption.
• Improved control of surfactant degradation and particle generation.

The relevant development package would need to evaluate extractables and leachables, silicone oil interactions, agitation stress, freeze-thaw exposure, and compatibility with the selected pen injector.

What formulations are protected or commercially differentiated?

The principal commercial differentiation for Omnitrope is likely to reside in the combination of formulation, container closure, cartridge, and delivery device rather than in the somatropin molecule itself.

Differentiation area	Commercial value	Primary technical barrier
Preservative-free formulation	High for sensitive patients	Sterility, packaging, cost
Higher-concentration formulation	High through lower injection volume	Viscosity, aggregation, device force
Prefilled pen	High through convenience	Device reliability and human factors
Smaller cartridge	Moderate to high for pediatric dosing	Dose accuracy and residual volume
Longer room-temperature in-use period	High for adherence and travel	Protein stability and microbial control
Reduced injection pain	Moderate to high	pH, osmolality, preservative concentration
Needle-free delivery	Niche but differentiated	Device cost and patient acceptance
Digital dose tracking	Moderate	Software, cybersecurity, reimbursement

A formulation patent could protect a specific combination of somatropin concentration, pH, buffer, stabilizer, surfactant, preservative, and storage profile. A device patent could cover the cartridge geometry, dose-setting mechanism, needle attachment, or administration sequence. A method-of-use patent could target a dosing schedule or patient subgroup, although such claims may face greater validity and enforceability challenges than composition claims.

No commercial strategy should assume that an excipient combination is patentable merely because it improves stability. Patentability generally depends on a technically defined composition, measurable performance benefit, and non-obvious selection or interaction among the components.

When does Omnitrope lose exclusivity?

Somatropin is an established recombinant protein, and broad active-ingredient exclusivity is no longer the main barrier to competition. The relevant protection layers are regulatory exclusivity, formulation patents, device patents, manufacturing know-how, trademarks, and market-access arrangements.

Protection layer	Omnitrope relevance
Somatropin composition patents	Generally limited because the molecule is long established
Regulatory exclusivity	Historical significance; depends on jurisdiction and product pathway
Formulation patents	Potentially relevant for specific compositions
Device patents	Potentially relevant for cartridges and injection pens
Method-of-use patents	May cover selected indications or dosing regimens
Trade secrets	Important for cell culture, purification, refolding, and quality control
Trademark protection	Protects the Omnitrope brand, not the active ingredient
Biosimilar or follow-on competition	Commercially significant

Exact patent expiration dates require a current jurisdiction-specific patent-family and litigation review. The U.S. biologic framework also differs from small-molecule products. Omnitrope is not analyzed solely through the traditional Orange Book system.

What is the Orange Book status of Omnitrope?

Omnitrope is a biologic product, so the Purple Book and the relevant biologics licensing framework are more important than the Orange Book. The Orange Book primarily lists approved small-molecule drug products and associated patents and exclusivity information. Biologic reference-product and biosimilar information is generally evaluated through FDA biologics records and the Purple Book.[2]

Omnitrope entered the U.S. market before the modern biosimilar pathway was fully implemented. FDA approved it under the then-available statutory pathway for recombinant human growth hormone products. Its approval history is therefore different from a later biosimilar approved under section 351(k) of the Public Health Service Act.[3]

For commercial diligence, the relevant questions are:

• Whether a competing product is approved under section 351(a) or 351(k).
• Whether the product is interchangeable.
• Whether any reference-product exclusivity period remains relevant.
• Whether device or formulation patents create practical launch barriers.
• Whether state substitution rules permit automatic pharmacy substitution.

Which companies are challenging Omnitrope’s market position?

Somatropin competition includes originator products, follow-on biologics, biosimilar products, and branded generics. Major competing products have included:

Product	Company or commercial sponsor	Strategic relevance
Genotropin	Pfizer	Established branded somatropin with pen delivery
Humatrope	Eli Lilly	Established branded somatropin
Norditropin	Novo Nordisk	Strong pen and pediatric endocrinology presence
Saizen	Merck Serono in relevant markets	Established international competitor
Nutropin	Historical Genentech/Roche product	Market precedent
Omnitrope	Sandoz	Follow-on and biologic competition
Ngenla	Pfizer	Long-acting growth-hormone alternative
Skytrofa	Ascendis Pharma	Long-acting growth-hormone alternative

The most important competitive threat is not always another daily somatropin. Long-acting growth-hormone products can compete through reduced injection frequency, even when their excipient systems differ materially from Omnitrope.

How strong is the Omnitrope patent estate?

The apparent strength of an Omnitrope patent estate depends on whether the relevant rights cover the product itself, its device, or manufacturing technology.

Composition patents

Composition claims directed broadly to somatropin are likely to be weak as commercial barriers because recombinant human growth hormone has been used for decades. Narrower claims may still protect:

• A defined concentration range.
• A specific stabilizer and surfactant combination.
• A selected pH range.
• A low-aggregate profile.
• A preservative-free multidose system.
• A formulation with a specified storage or in-use profile.

Device patents

Device rights may provide stronger practical protection if the product depends on a proprietary cartridge or injector. A generic or follow-on manufacturer could avoid some claims by using a different pen architecture, but that may increase development and human-factors costs.

Manufacturing patents and trade secrets

Manufacturing know-how can be more important than published formulation claims. Relevant areas include:

• Host-cell expression.
• Inclusion-body recovery.
• Protein refolding.
• Chromatographic purification.
• Removal of host-cell proteins and DNA.
• Control of aggregation and oxidation.
• Aseptic filling into cartridges.
• Container-closure qualification.

Manufacturing trade secrets are difficult for competitors to challenge directly. They can, however, be bypassed through an independent process if the competitor demonstrates comparability and meets regulatory requirements.

What generic entry risks exist for Omnitrope?

Omnitrope faces several forms of entry risk.

Follow-on biologic risk

A competing somatropin product may avoid the need to duplicate every aspect of Omnitrope’s formulation. Regulatory review generally focuses on the proposed product’s quality, safety, and efficacy under the applicable pathway. A competitor may use a different excipient system if it can demonstrate product quality and clinical suitability.

Device bypass risk

A competitor can reduce exposure to device patents by using:

• A disposable prefilled syringe.
• A proprietary pen with a different dose-setting mechanism.
• A multidose vial.
• A cartridge with different dimensions.
• A reusable injector with a new drive system.

This makes device patents commercially important but less likely to block the entire market.

Formulation design-around risk

A formulation competitor can alter the buffer, stabilizer, surfactant, preservative, or concentration while maintaining the same active ingredient. Narrow formulation claims may therefore have limited blocking power unless they cover an essential stability advantage.

Long-acting replacement risk

Long-acting growth-hormone products create a different form of substitution risk. They may reduce weekly injection burden and command premium reimbursement. Omnitrope must compete on price, dose flexibility, familiarity, and established supply reliability.

What commercial opportunities exist for Omnitrope excipients?

The strongest opportunities are linked to patient convenience and total treatment cost.

Preservative-free Omnitrope

A preservative-free presentation could address patients who experience local reactions or prefer single-dose packaging. The opportunity is strongest in specialty pharmacy and pediatric endocrinology channels, where adherence and tolerability can influence therapy persistence.

Higher-concentration Omnitrope

A higher-concentration formulation could reduce injection volume. It may be attractive for larger pediatric and adult patients, but development must control viscosity, dose accuracy, injection force, and aggregation.

Extended in-use stability

Improved in-use stability could support travel, school attendance, and reduced wastage. A product that tolerates limited periods outside refrigeration would have a clear practical advantage, provided the labeling is supported by stability data.

Pain-reduction formulation

A formulation with optimized pH, osmolality, preservative content, and injection volume could reduce discomfort. This opportunity is commercially meaningful because repeated injections can affect adherence, particularly in children.

Device-compatible excipient systems

The excipient system should be developed together with the primary container and injector. Important variables include:

• Silicone oil exposure.
• Elastomer compatibility.
• Protein adsorption.
• Delivered-dose accuracy.
• Needle gauge.
• Injection force.
• Residual volume.
• Cartridge orientation during storage.

An excipient change that improves molecular stability but causes dose variability or device failure has limited commercial value.

How does Omnitrope compare with long-acting growth-hormone products?

Attribute	Omnitrope	Long-acting growth hormone
Dosing frequency	Typically daily	Weekly or otherwise reduced frequency
Formulation priority	Refrigerated stability and multidose use	Extended-release or depot performance
Excipient complexity	Conventional protein-injection system	More complex delivery technology
Device requirements	Pen or cartridge compatibility	Often specialized injector or prefilled system
Main commercial advantage	Established product and dose flexibility	Fewer injections
Main commercial risk	Price and convenience pressure	Higher cost and manufacturing complexity
Patent exposure	Formulation, device, manufacturing	Delivery platform and formulation patents

Omnitrope can remain competitive where physicians value established somatropin experience, flexible titration, and lower acquisition cost. Long-acting products are better positioned where injection frequency is the primary treatment barrier.

What FDA and regulatory issues affect an excipient-led Omnitrope strategy?

FDA changes to the excipient system would generally require a regulatory submission appropriate to the extent of the change. Critical considerations include:

• Comparative analytical characterization.
• Stability under long-term and accelerated conditions.
• Subvisible and visible particulate testing.
• Container-closure integrity.
• Extractables and leachables.
• Sterility and antimicrobial effectiveness.
• Delivered-dose uniformity.
• Device compatibility.
• Human-factors validation.
• Immunogenicity risk assessment.
• Clinical bridging where analytical similarity is insufficient.

For a biologic, a formulation change can affect critical quality attributes and may create a comparability burden. An excipient strategy that reduces preservative exposure but introduces a new degradation pathway may produce a more difficult regulatory package than the original product.

What licensing opportunities exist around Omnitrope excipients and delivery?

Licensing opportunities are most credible in four areas:

1. Proprietary pen injectors with lower injection force.
2. Stabilized high-concentration somatropin formulations.
3. Preservative-free multidose packaging.
4. Extended-temperature-use technologies.

Potential partners include excipient suppliers, combination-product developers, specialty pharmaceutical companies, and device manufacturers. A license should be valued against freedom-to-operate risk, regulatory comparability requirements, manufacturing scale-up, and reimbursement potential.

A formulation license has greater value when it provides a measurable product advantage, such as a longer shelf life, lower injection volume, room-temperature stability, or reduced aggregation. A generic excipient substitution without a documented commercial benefit is unlikely to support meaningful royalty economics.

Key Takeaways

• Omnitrope uses a conventional somatropin formulation based on phosphate buffer, glycine, phenol, poloxamer 188, and water for injection.
• The main commercial opportunity is not broad molecule exclusivity. It is differentiated formulation and delivery.
• Preservative-free, higher-concentration, lower-pain, and extended in-use stability products have the clearest opportunity.
• Device and container patents may create more practical barriers than broad somatropin composition claims.
• Omnitrope is evaluated primarily through biologics regulatory records and Purple Book concepts rather than traditional Orange Book analysis.
• Follow-on somatropin products can design around narrow formulation claims.
• Long-acting growth-hormone products are the main convenience-driven competitive threat.
• Manufacturing know-how, cartridge compatibility, and device performance should be assessed alongside published patent claims.

FAQs

Can a competitor use different excipients from Omnitrope?

Yes. A competing somatropin product may use a different buffer, stabilizer, surfactant, or preservative if it satisfies applicable quality, safety, efficacy, and regulatory requirements.

Is phenol essential to Omnitrope’s commercial performance?

Phenol supports multidose preservation, but it is not inherently essential to somatropin activity. Removing it would require a different sterility, packaging, and in-use strategy.

Would a preservative-free Omnitrope product be patentable?

It could be patentable if the product combines a technically defined formulation and packaging system with a non-obvious stability, sterility, or usability benefit. Preservative removal alone may not support strong patent protection.

Can a biosimilar manufacturer avoid Omnitrope’s pen-device patents?

Potentially. A competitor can use a different injector, syringe, vial, or cartridge architecture, subject to regulatory, human-factors, and freedom-to-operate requirements.

Is Omnitrope exposed to substitution by weekly growth-hormone products?

Yes. Weekly products can compete by reducing injection frequency, although pricing, reimbursement, indication coverage, clinical familiarity, and device performance determine the rate of substitution.

References

1. U.S. Food and Drug Administration. (2023). Omnitrope (somatropin) injection prescribing information. Sandoz Inc.
2. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
3. U.S. Food and Drug Administration. (2006). FDA approves Omnitrope, the first follow-on protein product approved in the United States.
4. European Medicines Agency. (2006). Omnitrope: European public assessment report.
5. U.S. National Library of Medicine. (2024). DailyMed: Omnitrope somatropin injection, solution.